India, April 10 -- Hyderabad-based pharmaceutical firm Dr. Reddy's Laboratories has announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in Germany throughits step-down subsidiary betapharm.

The launch marks the company's entry into digital therapeutics in Europe. Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Last year, Dr. Reddy's entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, for the marketing and distribution of Nerivio in multiple markets.

Migraines are known to have a disproportionate impact o...